Headquartered in Emeryville, CA Fiscal year ends September NASDAQ: MGX metagenomi.co
Metagenomi Therapeutics, Inc. (Nasdaq: MGX) is a clinical-stage in vivo genome editing company developing potentially curative genetic medicines. It was founded on metagenomics, the study of genetic material recovered from the natural environment, which it uses to discover novel CRISPR gene-editing tools, including its proprietary Type V CRISPR nuclease MG29-1. The company aims to correct genetic mutations through site-specific deletion, insertion and correction. Its lead, wholly owned program is MGX-001 for hemophilia A. MGX-001 is a one-time treatment that combines an AAV-delivered promoterless FVIII gene with LNP-delivered MG29-1 mRNA and an albumin-targeting guide RNA, so that FVIII is integrated at the albumin locus and expressed under the native albumin promoter. The FDA cleared the MGX-001 IND in November 2026, and the company plans to start the global Phase 1/2 INTEGR8 trial in the first half of 2027. Metagenomi is also exploring other protein-deficiency diseases using the same albumin-locus gene integration approach and has partnered assets targeting cardiometabolic diseases. It focuses on indications with well-understood biology and defined regulatory pathways. Its current revenue comes from collaboration agreements. Updated
A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted insider buying at some biotech companies.
Metagenomi Therapeutics, Inc. (Nasdaq: MGX) is a clinical-stage in vivo genome editing company developing potentially curative genetic medicines.
The Wall Street consensus 12-month price target for MGX is $7.00.
